Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Coherus Oncology (CHRS) Other Non Operating Income: 2012-2024

Historic Other Non Operating Income for Coherus Oncology (CHRS) over the last 13 years, with Dec 2024 value amounting to -$12.6 million.

  • Coherus Oncology's Other Non Operating Income rose 2.74% to $2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $7.3 million, marking a year-over-year increase of 193.68%. This contributed to the annual value of -$12.6 million for FY2024, which is 330.94% down from last year.
  • Per Coherus Oncology's latest filing, its Other Non Operating Income stood at -$12.6 million for FY2024, which was down 330.94% from $5.5 million recorded in FY2023.
  • Coherus Oncology's 5-year Other Non Operating Income high stood at $5.5 million for FY2023, and its period low was -$12.6 million during FY2024.
  • In the last 3 years, Coherus Oncology's Other Non Operating Income had a median value of -$6.2 million in 2022 and averaged -$4.5 million.
  • As far as peak fluctuations go, Coherus Oncology's Other Non Operating Income tumbled by 2,098.59% in 2022, and later spiked by 187.90% in 2023.
  • Over the past 5 years, Coherus Oncology's Other Non Operating Income (Yearly) stood at $554,000 in 2020, then slumped by 151.08% to -$283,000 in 2021, then crashed by 2,098.59% to -$6.2 million in 2022, then skyrocketed by 187.90% to $5.5 million in 2023, then slumped by 330.94% to -$12.6 million in 2024.